PBX1 and leukemia: The mutation of PAX5 occurs in 6.9% of E2A-PBX1+ B-ALL patients, while an increased copy number of AKT3 occurs in 92%, which is closely related to relapsed and refractory leukemia (Zhou et al., 2021).